
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics Inc. has demonstrated a strong financial performance, with Q3 2025 revenue increasing by 63.3% year-over-year to $27.3 million, significantly surpassing previous estimates by $3.8 million. The company's management has raised revenue projections for FY25 by over $6 million to a target exceeding $96.5 million, reflecting confidence in ongoing growth. Furthermore, the substantial rise in new patient starts, particularly from conversions of multiple daily injection patients, coupled with a higher mix of higher-margin sales through the pharmacy channel, underpins a positive outlook for robust revenue growth into 2026 and beyond.
Bears say
Beta Bionics Inc faces significant challenges that negatively impact its financial outlook, including the potential failure to gain meaningful market share for its iLet product amid competitive pressures and difficulties in securing sustained penetration in the pharmacy channel. The company's EBITDA loss of $12.2 million exceeds prior estimates, and slower than anticipated adoption due to the absence of FDA label expansion further complicates revenue generation. Additionally, prospective regulatory changes in Medicare reimbursement and the need for additional capital could lead to shareholder dilution, compounding the financial risks the company faces.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares